Sangui Biotech International, Inc. Reports Earnings Results for the First Nine Months of Fiscal Year 2018
May 03, 2018
Share
Sangui Biotech International, Inc. reported earnings results for the first nine months of fiscal year 2018. In the first nine months of fiscal year 2018, the company achieved revenues from royalty income and product sales of USD 65,273. In the same period of the previous year the comparable revenue amounted to USD 47,186. Due to increased revenues of the wound spray Granulox, the resulting royalty income in the first nine months increased by 38% compared to the same period of the previous year. Nine month operating loss decreased USD 116,346 to USD 177,923 from the prior year. The operating loss for the third quarter of 2018 decreased by USD 6,856 year-on-year to USD 68,798.
Sangui Biotech International, Inc. focuses on the development of pharmaceutical, medical and cosmetic products. The Company develops its products through its German subsidiary, SanguiBioTech AG (Sangui GmbH). It is engaged in seeking to market and selling its products through partnerships with industry partners across the world. It focuses on the development of oxygen carriers capable of providing oxygen transport in humans in the event of acute and/or chronic lack of oxygen due to arterial occlusion, anemia or blood loss whether due to surgery, trauma, or other causes. It focuses its development and commercialization efforts on such artificial oxygen carriers by reproducing and synthesizing polymers out of native hemoglobin of defined molecular sizes. It offers external applications of oxygen transporters in the medical and cosmetic fields in the form of sprays for the healing of chronic wounds and of gels and emulsions for the regeneration of the skin.
SANGUI BIOTECH INTERNATIONAL, INC. 
